Total
0
Shares
- Rugby Player, James Graham
Rugby Player, James Graham
Source: Wide World of Sports – Nine
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal cannabis company Impression Healthcare (IHL) has announced rugby league footballer James Graham has joined the company’s advisory board
  • James will assist with the commercial development of Impression’s IHL-216A, a treatment for concussions and traumatic brain injury
  • He’ll also build the company’s relationship with the Rugby League Players Association and develop an arrangement with the NRL for the use of IHL-216A throughout the elite competition
  • Commenting on his new appointment, James says he’s passionate about understanding and treating concussions and wants to help Impression any way he can
  • Currently, James’ contract with the board covers two years
  • Impression is up 2.04 per cent on the market this morning, trading for five cents per share

Medicinal cannabis company, Impression Healthcare (IHL) has announced rugby league footballer James Graham has joined the company’s advisory board for two years.

James will assist with the commercial development of IHL-216A for the treatment of concussion and traumatic brain injury.

Speaking of their new board member, Impression says the NRL athlete is a popular and celebrated premiership rugby player. James played for the St. George Illawarra Dragons in the National Rugby League and has also played for England and Great Britain at an international level.

He is also a well-known commentator and weekly contributor to the TV program, NRL 360 on Fox Sports.

As part of the advisory board, James will help Impression develop ‘real world’ aspects of the clinical program, build the company’s relationship with the Rugby League Players Association and develop an arrangement with the NRL for the use of IHL-216A throughout the elite competition.

James says he is passionate about understanding and treating concussions and wants to help any way he can.

“Having been involved in contact sport all my adult life, it is almost impossible not to have an interest in concussion and its possible side effects. Many times, I have questioned the long-term health implications and what, if anything, I can do about it,” he said.

“I feel working with Impression gives me a great platform to do so, and I am excited for what the future holds with the IHL-216A program,” he added.

CEO Joel Latham is pleased to have a respected and influential Australian sporting figure join the team.

“I have been impressed with James’ extensive knowledge of many aspects of traumatic brain injury and he shares our strong view that we must make changes to ameliorate the symptoms of, and damage caused by, concussions in contact sports,” he said.

Impression is up 2.04 per cent on the market this morning, trading for five cents per share at 10:04 am AEST.

IHL by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.